BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22839443)

  • 1. [Galectin 3--a new biomarker for diagnostics and outcome of chronic heart failure].
    Lakomkin SV; Skvortsov AA; Goriunova TV; Masenko VP; Tereshchenko SN
    Kardiologiia; 2012; 52(3):45-52. PubMed ID: 22839443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure.
    Hrynchyshyn N; Jourdain P; Desnos M; Diebold B; Funck F
    Arch Cardiovasc Dis; 2013 Oct; 106(10):541-6. PubMed ID: 24090952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The involvement of galectin-3 in heart failure].
    Kałan M; Witczak A; Mosiewicz J; Donica H
    Postepy Hig Med Dosw (Online); 2015 Sep; 69():1107-13. PubMed ID: 26400896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of Galectin-3 in Acute Myocardial Infarction.
    Li M; Yuan Y; Guo K; Lao Y; Huang X; Feng L
    Am J Cardiovasc Drugs; 2020 Aug; 20(4):333-342. PubMed ID: 31784887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of galectin 3 as myofibrosis marker in clinical cardiology].
    Málek F
    Vnitr Lek; 2014 Apr; 60(4):327-30. PubMed ID: 24985993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galectin-3: a novel mediator of heart failure development and progression.
    de Boer RA; Voors AA; Muntendam P; van Gilst WH; van Veldhuisen DJ
    Eur J Heart Fail; 2009 Sep; 11(9):811-7. PubMed ID: 19648160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of galectin-3 in patients with heart failure.
    Bošnjak I; Selthofer-Relatić K; Včev A
    Dis Markers; 2015; 2015():690205. PubMed ID: 25960597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.
    Lok DJ; Van Der Meer P; de la Porte PW; Lipsic E; Van Wijngaarden J; Hillege HL; van Veldhuisen DJ
    Clin Res Cardiol; 2010 May; 99(5):323-8. PubMed ID: 20130888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin-3 and heart failure: prognosis, prediction & clinical utility.
    Filipe MD; Meijers WC; Rogier van der Velde A; de Boer RA
    Clin Chim Acta; 2015 Mar; 443():48-56. PubMed ID: 25446877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of plasma biomarkers in discharged heart failure patients: role of galectin-3.
    Leone M; Iacoviello M
    Minerva Cardioangiol; 2016 Apr; 64(2):181-94. PubMed ID: 26426300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation.
    Beiras-Fernandez A; Weis F; Rothkopf J; Kaczmarek I; Ledderose C; Dick A; Keller T; Beiras A; Kreth S
    Ann Transplant; 2013 Nov; 18():643-50. PubMed ID: 24264380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using galectin-3 to reduce heart failure rehospitalization.
    Xue Y; Maisel A; Peacock WF
    Future Cardiol; 2014 Mar; 10(2):221-7. PubMed ID: 24762249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.
    van Kimmenade RR; Januzzi JL; Ellinor PT; Sharma UC; Bakker JA; Low AF; Martinez A; Crijns HJ; MacRae CA; Menheere PP; Pinto YM
    J Am Coll Cardiol; 2006 Sep; 48(6):1217-24. PubMed ID: 16979009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galectin-3, a prognostic marker--and a therapeutic target?
    Pereira AR; Menezes Falcão L
    Rev Port Cardiol; 2015 Mar; 34(3):201-8. PubMed ID: 25746675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-3 in heart failure with preserved ejection fraction.
    de Boer RA; Edelmann F; Cohen-Solal A; Mamas MA; Maisel A; Pieske B
    Eur J Heart Fail; 2013 Oct; 15(10):1095-101. PubMed ID: 23650131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers in heart failure: the past, current and future.
    Sarhene M; Wang Y; Wei J; Huang Y; Li M; Li L; Acheampong E; Zhengcan Z; Xiaoyan Q; Yunsheng X; Jingyuan M; Xiumei G; Guanwei F
    Heart Fail Rev; 2019 Nov; 24(6):867-903. PubMed ID: 31183637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH.
    Meijers WC; de Boer RA; van Veldhuisen DJ; Jaarsma T; Hillege HL; Maisel AS; Di Somma S; Voors AA; Peacock WF
    Eur J Heart Fail; 2015 Dec; 17(12):1271-82. PubMed ID: 26466857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galectin-3 in cardiac remodeling and heart failure.
    de Boer RA; Yu L; van Veldhuisen DJ
    Curr Heart Fail Rep; 2010 Mar; 7(1):1-8. PubMed ID: 20425490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers and diagnostics in heart failure.
    Gaggin HK; Januzzi JL
    Biochim Biophys Acta; 2013 Dec; 1832(12):2442-50. PubMed ID: 23313577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of galectin-3 in heart failure and cardiovascular disease.
    Zhong X; Qian X; Chen G; Song X
    Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):197-203. PubMed ID: 30372548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.